Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Javle

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Cancer Medicine|June 11, 2020
Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinomaJane E Rogers, Jonathan D Mizrahi, Lianchun Xiao, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with m<i>IDH1</i> cholangiocarcinomaJ W Valle, G K Abou-Alfa, R K Kelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2025
Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor ApproachTaiwo Adesoye, Ecaterina E Dumbrava, Kanwal P S Raghav, et al.
Journal of Chemotherapy (Florence, Italy)|November 28, 2006
Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survivalL Leichman, D Lawrence, C G Leichman, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|January 15, 2020
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or olderJonathan D Mizrahi, Jane E Rogers, Kenneth R Hess, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomenKilian Salerno May, Nikhil I Khushalani, Rameela Chandrasekhar, et al.
ESMO Open|March 18, 2026
Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301G K Abou-Alfa, I Borbath, S Roychowdhury, et al.
The Journal of Molecular Diagnostics : JMD|February 17, 2022
Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic ProfilingIan M Silverman, Meijuan Li, Karthikeyan Murugesan, et al.
Cancer Chemotherapy and Pharmacology|June 11, 2005
S-phase modulation by irinotecan: pilot studies in advanced solid tumorsN Ramnath, N Khushalani, K Toth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response AnalysisRanda Tao, Sunil Krishnan, Priya R Bhosale, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Cancer Medicine|June 11, 2020
Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinomaJane E Rogers, Jonathan D Mizrahi, Lianchun Xiao, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with m<i>IDH1</i> cholangiocarcinomaJ W Valle, G K Abou-Alfa, R K Kelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2025
Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor ApproachTaiwo Adesoye, Ecaterina E Dumbrava, Kanwal P S Raghav, et al.
Journal of Chemotherapy (Florence, Italy)|November 28, 2006
Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survivalL Leichman, D Lawrence, C G Leichman, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|January 15, 2020
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or olderJonathan D Mizrahi, Jane E Rogers, Kenneth R Hess, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomenKilian Salerno May, Nikhil I Khushalani, Rameela Chandrasekhar, et al.
ESMO Open|March 18, 2026
Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301G K Abou-Alfa, I Borbath, S Roychowdhury, et al.
The Journal of Molecular Diagnostics : JMD|February 17, 2022
Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic ProfilingIan M Silverman, Meijuan Li, Karthikeyan Murugesan, et al.
Cancer Chemotherapy and Pharmacology|June 11, 2005
S-phase modulation by irinotecan: pilot studies in advanced solid tumorsN Ramnath, N Khushalani, K Toth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response AnalysisRanda Tao, Sunil Krishnan, Priya R Bhosale, et al.
Pageof 10